GlassScriptPhysician profile
Chase Douglas Smith
NPI 1598086662
$5,917.81
in general payments reported to CMS, 2019-2025
11 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $564 · 2021: $28.52 · 2022: $1,668 · 2023: $83.17 · 2024: $314 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,542 · Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,542.30 |
| Food and Beverage | $1,015.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prime Surgical, LLC | $2,808.19 | 2019-2025 | |
| Arthrex, INC. | $2,348.24 | 2020-2025 | |
| Smith+Nephew, INC. | $334.91 | 2022-2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Depuy Synthes Sales INC. | $155.71 | 2019-2023 | Orthovisc, Monovisc, Na |
| Medtronic Vascular, INC. | $81.49 | 2019 | |
| Inspire Medical Systems, INC. | $67.08 | 2024 | Inspire |
| Amgen INC. | $40.68 | 2019-2021 | |
| Vericel Corporation | $25.31 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $25.24 | 2023 | Exparel, Iovera, Zilretta |
| Avanos Medical | $17.19 | 2023 | Trivisc Sodium Hyaluronate |
| Sanofi-Aventis U.S. LLC | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.